Previous close | 0.5410 |
Open | 0.5640 |
Bid | 0.5188 x 200 |
Ask | 0.5704 x 200 |
Day's range | 0.5300 - 0.5700 |
52-week range | 0.3020 - 1.9900 |
Volume | |
Avg. volume | 154,782 |
Market cap | 13.84M |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9000 |
Earnings date | 17 May 2024 - 21 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.67 |
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interim results from its randomized, controlled
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion a
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to ov